# Final Review

**Purpose:** Log the paper's final state after all revisions
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-23T22:14:28.219253
**Response ID:** resp_0e9438a604f83f5b006973e41e6ff88194a8abbc8a4f5dad8b
**Tokens:** 9734 in / 5210 out
**Response SHA256:** fa8a4e3d77704439

---

## Referee Report (general-interest top journal standard)

### Summary
The paper asks whether *mandatory* PDMP query requirements reduce opioid overdose mortality, using staggered adoption across U.S. jurisdictions and CDC VSRR mortality data (2015–2020). The headline result is null: TWFE implies +2.0% (SE 5.8%), Sun–Abraham yields −2.5% (SE 2.8%). The event study shows at least one statistically significant pre-trend (the lead at event time −3; p = 0.007), which the authors appropriately flag.

At a top general-interest journal bar, the paper is not close in its current form. The central problem is that the available outcome panel starts in 2015, making many jurisdictions always-treated and leaving identification to hinge on a small set of late adopters vs a small and arguably non-comparable “never-treated” group, with evidence of differential pre-trends. As written, the paper is best viewed as a careful *diagnostic* of why this specific design/data combination struggles—not as a credible policy evaluation delivering interpretable causal effects.

Below I give a rigorous format/inference check and then focus on the deeper issues: identification, data construction, and what would be required to make this publishable.

---

# 1. FORMAT CHECK

**Length**
- The provided draft appears to be **~19 pages including figures** (pages shown run to 19, with the appendix table and references included within that count). This is **below the 25-page minimum** requested in the prompt and below typical AER/QJE/JPE/ReStud/ECTA expectations for a full empirical paper. The paper currently reads like a high-quality working note rather than a journal-length contribution.

**References**
- The bibliography is **far too thin** for a top journal (≈7 items: Buchmueller & Carey; Patrick et al.; Goodman-Bacon; Sun–Abraham; Kaestner–Ziedan; Mallatt; CDC). It omits major DiD method papers, many PDMP/opioid mortality papers, and essentially all of the broader policy evaluation literature relevant to supply-side opioid interventions.

**Prose (paragraph form vs bullets)**
- Most sections are in paragraph form. However, **Section 5 “Discussion and Conclusion” includes a numbered list** (“Our main findings are: 1. 2. 3.”). Lists are fine sparingly, but top journals usually expect the *core argument* to be developed in paragraphs with a narrative arc (especially in Introduction/Discussion).

**Section depth (3+ substantive paragraphs each)**
- **Introduction (Section 1):** ~3+ paragraphs; acceptable.
- **Data (Section 2):** detailed; acceptable.
- **Empirical Strategy (Section 3):** relatively short; could be expanded substantially (e.g., explicit estimands, weighting, comparison sets, treatment timing coding).
- **Results (Section 4):** has multiple subsections, but each is quite brief; for a top journal, the results section is underdeveloped.
- **Discussion (Section 5):** short; needs a deeper synthesis and interpretation.

**Figures**
- Figures shown do have axes/legends, but **font size/legibility looks marginal** in the provided render (especially event study confidence band figure and cohort trend figure). For publication quality, axes labels and notes must be readable at journal column width.
- Map (Figure 2) is a nice descriptive figure, but it is not central to identification.

**Tables**
- Tables contain real numbers, SEs, N, etc. No placeholders.

**Bottom line on format:** Not at top-journal length, and the literature coverage is far below standard.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### 2(a) Standard errors
- PASS: Tables report SEs in parentheses (Table 3), event-study SEs are discussed, and clustering is described.

### 2(b) Significance testing
- PASS: p-values are reported in text (e.g., abstract, Section 4.2) and stars are defined in table notes (though not used).

### 2(c) Confidence intervals
- **FAIL (as presented):** The main tables do **not** report 95% confidence intervals. Top journals generally require CIs (either in tables or clearly in text/figures).
  - You can easily add them. For example, using Table 3:
    - TWFE: β = 0.020, SE = 0.058 ⇒ 95% CI ≈ **[−0.094, 0.134]** in logs, i.e. roughly **[−9.0%, +14.3%]**.
    - Sun–Abraham ATT: −0.025 (0.028) ⇒ 95% CI ≈ **[−0.080, 0.030]**, i.e. roughly **[−7.7%, +3.0%]**.
  - These wide intervals are substantively important and should be front-and-center.

### 2(d) Sample sizes
- PASS: Observations and number of jurisdictions are reported (Table 3). Data attrition is described in Section 2.1.

### 2(e) DiD with staggered adoption
- **Mixed; method name-checking is not enough.**
  - The paper does run TWFE (Equation 1) even though treatment timing is staggered. That is acceptable only if used descriptively and explicitly subordinated to heterogeneity-robust estimators.
  - The Sun–Abraham estimator is a serious step in the right direction, but the paper does **not** provide enough detail about:
    - Which cohorts identify which event times (“clean comparisons” set),
    - Effective weights / influence of each cohort (or a Goodman-Bacon-type decomposition for TWFE),
    - How sensitive the Sun–Abraham ATT is to choice of omitted event time, binning of leads/lags, and limited support.
  - **Most importantly:** identification is hanging by a thread because the outcome panel begins in 2015, forcing exclusion of early adopters and leaving a small sample of late adopters.

### 2(f) RDD
- Not applicable.

### Additional inference issues not addressed (serious at top-journal bar)
1. **Few clusters / clustered SE reliability.** The regressions cluster at the jurisdiction level with ~27 or 41 clusters depending on estimator (Table 3). This is borderline but often acceptable; however, given the small effective sample and leverage concerns, the paper should report **wild cluster bootstrap p-values** (e.g., Roodman et al. style) and/or **CR2 (Bell–McCaffrey) small-sample corrections**.
2. **Outcome functional form.** Using **log(count+1)** on annual counts (not rates) raises:
   - Heteroskedasticity and population size confounding (large states dominate).
   - Mechanical issues for low-count states and those with suppressed/predicted values.
   - For mortality counts, a **Poisson/PPML with population offset** (or negative binomial) is often more credible and interpretable, and tends to handle zeros naturally.
3. **Treatment timing measurement error.** You code mid-year effective dates as treated for the entire calendar year (Appendix Table A1 notes this). This creates **systematic attenuation** that is not a minor footnote—it directly biases the first treatment year effect toward zero and distorts dynamics.

**Bottom line on methodology:** The paper has basic inference, but it is **not publishable** in a top journal without (i) CI reporting, (ii) small-cluster-robust inference, (iii) a more credible outcome model (rates/offsets), and (iv) serious treatment-timing measurement fixes (monthly analysis or partial-year exposure).

---

# 3. IDENTIFICATION STRATEGY

### Credibility
As written, **identification is not credible enough for causal claims**, and the authors’ own event study flags this (Section 4.2: significant lead at t = −3, p = 0.007). At top-journal standards, a single significant lead is not automatically fatal, but here it is symptomatic of deeper problems:

1. **Always-treated cohorts due to late outcome start (2015).**
   - Section 2.1 acknowledges that 2012–2015 adopters are always-treated and provide no pre-trends.
   - This is not just a limitation; it fundamentally changes the estimand and the comparison set. In practice, the effect is identified by a **small number of 2016–2020 adopters** vs **7 “never-treated” jurisdictions** (AK, CA, CO, DC, MI, MO, MT) that are highly non-random and arguably systematically different.

2. **Endogenous adoption / differential epidemic phase.**
   - Your cohort plots (Figure 3) and narrative emphasize that adoption timing correlates with epidemic severity and timing (prescription wave vs fentanyl wave). That is exactly the kind of endogenous policy response that breaks parallel trends.

3. **Short panel / limited pre-trends.**
   - With 2015–2020 annual data, late adopters have at most a few pre-years. This makes pre-trend testing low-power and highly sensitive to noise, while simultaneously leaving little room for convincing design diagnostics.

4. **Bad controls / contamination.**
   - The “never-treated” set includes places with meaningful PDMP activity but not “comprehensive mandates” under your strict definition (e.g., California; Michigan partial requirement). If “never-treated” are partially treated, you bias toward zero; if they differ structurally, you induce non-parallel trends.

### Assumptions discussion
- The paper discusses parallel trends and heterogeneity concerns (Sections 3.1–3.3, 4.2), which is good.
- But for top-journal credibility, you need much more:
  - A clear statement of the target estimand (policy-on vs policy-off; contemporaneous vs dynamic; by opioid type).
  - Diagnostics showing which cohorts contribute to each event-time coefficient (support).
  - Sensitivity to alternative control groups and alternative adoption codings.

### Placebos and robustness
- Robustness is minimal (Section 4.5: opioid share of overdoses). That is not enough.
- You need:
  - Placebo policies / placebo timing (randomized adoption dates within region).
  - Negative control outcomes (e.g., non-opioid mortality categories plausibly unaffected).
  - Alternative windows (extend to 2021–2023 and handle Michigan etc. via redefinition of controls rather than truncating).
  - Alternative treatment definitions (any mandate; partial mandate; delegate access; exemptions).

### Do conclusions follow from evidence?
- The authors are cautious, which is appropriate. However, several sentences still read like policy-effect conclusions (“PDMP mandates are associated with …” in Table 3 discussion) when the core message is really “this design cannot identify the effect with these data.”

**Bottom line on identification:** The paper currently demonstrates that *this particular staggered DiD with VSRR annualized data is not credible*, but it does not provide a credible alternative design. That is insufficient for a top outlet.

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology papers that must be cited/discussed (currently missing)
You cite Goodman-Bacon (2021) and Sun–Abraham (2021), but omit other foundational pieces that are standard in top-journal DiD work:

1. **Callaway & Sant’Anna (2021)** — group-time ATT estimator; transparent about comparison sets; often preferred when never-treated exist.
```bibtex
@article{CallawaySantAnna2021,
  author  = {Callaway, Brantly and Sant'Anna, Pedro H. C.},
  title   = {Difference-in-Differences with Multiple Time Periods},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {200--230}
}
```

2. **Borusyak, Jaravel & Spiess (2021)** — imputation / estimator perspective; clarifies what is identified under staggered designs.
```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event-Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year    = {2021}
}
```
(If you prefer published-only citations, you can cite later journal versions depending on availability; but at minimum acknowledge the approach.)

3. **Roth et al. (2023)** — pretrend testing / sensitivity in DiD event studies; directly relevant given your significant lead.
```bibtex
@article{RothSantAnnaBilinskiPoe2023,
  author  = {Roth, Jonathan and Sant'Anna, Pedro H. C. and Bilinski, Alyssa and Poe, John},
  title   = {What's Trending in Difference-in-Differences? A Synthesis of the Recent Econometrics Literature},
  journal = {Journal of Econometrics},
  year    = {2023},
  volume  = {235},
  number  = {2},
  pages   = {2218--2244}
}
```

4. **Conley & Taber (2011)** — inference in DiD with few treated groups; relevant given small effective treated cohorts.
```bibtex
@article{ConleyTaber2011,
  author  = {Conley, Timothy G. and Taber, Christopher R.},
  title   = {Inference with Difference in Differences with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year    = {2011},
  volume  = {93},
  number  = {1},
  pages   = {113--125}
}
```

### PDMP/opioid empirical literature missing (examples)
Your domain citations are far from comprehensive. At top-journal bar you need to engage: PDMP implementation vs mandates, prescribing vs mortality, substitution to illicit opioids, heterogeneous effects by opioid type, and adjacent opioid supply policies.

Examples to consider (verify exact bibliographic details as you finalize):
- Studies on PDMP effects on prescribing and mortality beyond Patrick et al. (2016), including heterogeneity by fentanyl era.
- Work on unintended consequences/substitution (prescription tightening → heroin/fentanyl).
- Comparative work on “must access” vs “must register” vs delegate access, etc.

Even if you keep the paper narrowly methodological (“why it’s hard to estimate”), you must still show command of the substantive PDMP debate and why your null differs from prior findings.

**Bottom line:** The literature review is not at a publishable standard for a top general-interest journal.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Mostly paragraph-based. The numbered list in Section 5 is acceptable stylistically, but the *overall narrative* still feels like a technical memo. Top journals demand a more compelling and coherent story.

### Narrative flow
- The Introduction is competent, but it does not sharply articulate a novel contribution beyond “we tried modern DiD and got null with limitations.” For a top journal, the paper must be framed as either:
  1) a credible causal estimate with a strong design, **or**
  2) a major methodological lesson with broad applicability and new tools/diagnostics.

Right now it is between these: it admits identification failure, but does not elevate that into a generalizable contribution (e.g., “crisis-response policy evaluation with late-start administrative outcomes: conditions for identification, proposed solutions, and empirical demonstration across multiple policies”).

### Sentence quality and accessibility
- Generally clear, with appropriate technical language.
- Missing: intuitive explanation of **what exactly Sun–Abraham is identifying given your sample truncation**, and why the pretrend at −3 is especially concerning given epidemic phase differences.

### Figures/tables self-contained
- Notes are present and fairly good.
- Improve legibility and add CIs to main results table.

---

# 6. CONSTRUCTIVE SUGGESTIONS (what would make this publishable)

To have a realistic chance at a top journal (or even AEJ:EP), you likely need a **redesign**, not incremental edits.

## A. Fix treatment timing and outcome frequency (high priority)
1. **Use monthly mortality** (VSRR is monthly; you already have monthly 12-month-ending series). Code treatment at the month level and estimate with appropriate time FE (month×year) or flexible seasonality.
2. Alternatively, compute **fraction-of-year exposure** (treated share of months in year) if you insist on annual outcomes.

## B. Use rates and appropriate count models
- Move from log(count+1) to:
  - **PPML with population offset** (preferred),
  - or log mortality **rates** (age-adjusted if possible).
- Report effects in deaths per 100,000 and implied death counts.

## C. Replace “never-treated” with a more credible counterfactual
Your never-treated set is small and idiosyncratic. Consider:
1. **Synthetic control / augmented synthetic control** per treated state (then aggregate).
2. **Border-pair designs** (county-level mortality if accessible; or state border discontinuities with commuting zones).
3. **Instrumental variables** is hard here, but if you propose it, it must be credible (e.g., legislative term limits or PDMP vendor shocks are sometimes used, but require serious defense).

## D. Explicitly target heterogeneity by opioid type and epidemic phase
Given the fentanyl transition, aggregate opioid deaths may mask substitution:
- Separate outcomes: prescription opioids vs heroin vs synthetic opioids (fentanyl) if feasible via ICD-10 categories.
- Show whether mandates reduce prescription-opioid deaths but increase fentanyl/heroin deaths (net zero), or nothing moves.

## E. Strengthen DiD implementation and diagnostics
1. Add **Callaway & Sant’Anna** group-time ATT estimates; show robustness across Sun–Abraham, C&S, and imputation estimators.
2. Provide **support plots**: which cohorts contribute to each k in the event study; trim leads/lags with poor support.
3. Address significant pretrend with:
   - sensitivity analyses (Roth-style),
   - alternative comparison sets (region-specific trends),
   - explicit epidemic-phase controls (though these can be “bad controls”; must be justified).

## F. Improve inference
- Use wild cluster bootstrap and/or CR2 corrections.
- Consider randomization inference based on adoption timing within region to show robustness.

## G. Reframe the contribution (if causal ID remains weak)
If you cannot obtain credible identification, you can still publish a valuable paper by reframing as:
- A systematic demonstration that **standard state-panel DiD designs fail** for crisis-response policies when (i) outcomes begin late, (ii) adoption is endogenous, (iii) treatment is mismeasured within-year, and (iv) controls are partially treated.
But then you must:
- Generalize beyond PDMPs (e.g., apply the same diagnostic framework to multiple opioid policies),
- Provide formal conditions, simulation, or partial identification bounds,
- Offer a clear methodological takeaway and best-practice recommendations.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Transparent about sample construction and limitations (Section 2.1; Section 5).
- Uses modern staggered-adoption tools (Sun–Abraham) rather than relying exclusively on TWFE.
- The paper does not overclaim; it flags the pretrend issue directly (Section 4.2).

### Critical weaknesses (publication-stopping)
1. **Identification is not credible with 2015–2020 annual data**: too many always-treated cohorts; small and non-random never-treated group; evidence of differential pre-trends.
2. **Treatment timing is mismeasured** (mid-year laws coded as full-year treated), mechanically attenuating effects and distorting dynamics.
3. **Outcome modeling is weak** for mortality counts (log(count+1), no population offset).
4. **Literature coverage is far below top-journal standard** (both methods and substantive PDMP research).
5. **Too short / underdeveloped** for a general-interest journal; results and interpretation need far more depth.

### Specific actionable improvements
- Move to monthly panel + correct exposure timing.
- Use PPML with population offset; report rate effects and implied deaths.
- Use C&S estimator and small-sample-robust inference.
- Rebuild control strategy (synthetic/border designs).
- Expand literature review substantially and sharpen contribution.

---

DECISION: REJECT AND RESUBMIT